Halozyme Therapeutics (HALO) Non-Current Deffered Revenue (2010 - 2023)

Halozyme Therapeutics (HALO) has 14 years of Non-Current Deffered Revenue data on file, last reported at $2.3 million in Q3 2023.

• On a quarterly basis, Non-Current Deffered Revenue fell 20.47% year-over-year to $2.3 million in Q3 2023; TTM through Sep 2023 was $2.3 million, a 20.47% decrease from a year earlier, with the FY2022 full-year figure at $2.3 million, down 10.95% from the prior year.
• Non-Current Deffered Revenue for Q3 2023 stood at $2.3 million, roughly flat from $2.3 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for HALO reached as high as $4.5 million in Q1 2019 and fell as low as $641000.0 in Q1 2020.
• Historically, Non-Current Deffered Revenue has averaged $2.3 million across 5 years, with a median of $2.3 million in 2022.
• Across the five-year window, Non-Current Deffered Revenue sank 85.78% in 2020 and surged 528.08% in 2021, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $1.2 million in 2019, then soared by 222.85% to $4.0 million in 2020, then tumbled by 37.16% to $2.5 million in 2021, then decreased by 10.95% to $2.3 million in 2022, then changed by 0.0% to $2.3 million in 2023.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $2.3 million in Q3 2023, $2.3 million in Q2 2023, and $2.3 million in Q1 2023.